Core Capital Management & Research inc. Invests $4.73 Million in Bristol Myers Squibb Company $BMY

Core Capital Management & Research inc. acquired a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 82,074 shares of the biopharmaceutical company’s stock, valued at approximately $4,729,000. Bristol Myers Squibb accounts for about 2.5% of Core Capital Management & Research inc.’s holdings, making the stock its 13th largest holding.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Life Cycle Investment Partners Ltd acquired a new position in Bristol Myers Squibb during the fourth quarter worth approximately $34,406,000. Lazard Asset Management LLC grew its stake in shares of Bristol Myers Squibb by 23.7% during the 1st quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock valued at $116,693,000 after buying an additional 368,193 shares during the period. Axxcess Wealth Management LLC increased its holdings in shares of Bristol Myers Squibb by 27.4% during the 4th quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock worth $5,322,000 after buying an additional 21,196 shares during the last quarter. Callan Family Office LLC purchased a new position in shares of Bristol Myers Squibb in the 2nd quarter worth $3,575,000. Finally, BlackRock Inc. boosted its holdings in Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after acquiring an additional 8,702,106 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Stock Down 0.4%

Shares of Bristol Myers Squibb stock opened at $64.46 on Thursday. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $68.64. The business has a 50-day moving average of $63.39 and a 200-day moving average of $60.03. The company has a market capitalization of $131.68 billion, a PE ratio of 14.20, a P/E/G ratio of 0.31 and a beta of 0.23.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.Bristol Myers Squibb’s quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter last year, the firm earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities analysts forecast that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 3.9%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is 55.51%.

Analysts Set New Price Targets

Several equities research analysts have commented on BMY shares. JPMorgan Chase & Co. upped their price target on Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Piper Sandler began coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set an “overweight” rating for the company. Raymond James Financial started coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “strong-buy” rating on the stock. Jefferies Financial Group downgraded shares of Bristol Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, August 5th. Finally, Sanford C. Bernstein upgraded Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $66.06.

Insiders Place Their Bets

In other news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. The trade was a 2.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.05% of the stock is currently owned by corporate insiders.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Promising arlo-cel multiple myeloma results: Bristol Myers reported positive topline results from the registrational Phase 2 QUINTESSENTIAL trial of arlocabtagene autoleucel, or arlo-cel, a potential first-in-class GPRC5D-directed CAR-T therapy. The results could strengthen BMY’s position in heavily pretreated multiple myeloma and expand its growth pipeline. Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial
• Positive Sentiment: Pipeline diversification opportunity: Analysts characterized the arlo-cel data as a potentially important addition to Bristol Myers’ cell-therapy portfolio. Success could eventually provide another commercial product to offset patent-expiration and competitive pressures affecting parts of the company’s existing portfolio. Will the Recent Pipeline Progress Boost BMY’s Portfolio Expansion?
• Neutral Sentiment: SOTYKTU growth potential: An industry report sees additional opportunities for BMY’s SOTYKTU in earlier-line treatment, injection-averse patients and new immune-mediated indications. The report is commercially supportive but does not represent a new company announcement or regulatory approval. SOTYKTU Clinical, Regulatory and Commercial Intelligence Report 2026
• Negative Sentiment: CAR-T safety concerns are weighing on the sector: Novartis paused eight experimental CAR-T trials after three patient deaths linked to severe immune reactions. Although the issue involves Novartis, it may increase investor scrutiny of cell-therapy safety, development costs and regulatory risks for BMY’s arlo-cel program. Could Bristol-Myers Squibb Outperform Novartis as CAR-T Safety Concerns Shake the Sector?
• Negative Sentiment: Investors initially sold the news: Reports indicate BMY shares moved lower despite the arlo-cel trial success, suggesting investors may be taking profits or focusing on unanswered questions around safety, approval timing and the therapy’s eventual commercial potential. Bristol-Myers Squibb Stock Heads Into the Open After a 3.2 Percent Drop

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.